Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.21
ACT's Cash-to-Debt is ranked lower than
86% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. ACT: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.4 Max: 41.17
Current: 0.21
0.02
41.17
Equity-to-Asset 0.62
ACT's Equity-to-Asset is ranked lower than
53% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACT: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.63 Max: 0.91
Current: 0.62
0.27
0.91
Debt-to-Equity 0.41
ACT's Debt-to-Equity is ranked lower than
58% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ACT: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
ACT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.29 Max: 1.68
Current: 0.41
0.01
1.68
Debt-to-EBITDA -15.65
ACT's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ACT: -15.65 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ACT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.65  Med: 4.46 Max: 15.49
Current: -15.65
-15.65
15.49
Piotroski F-Score: 6
Altman Z-Score: 0.74
Beneish M-Score: -2.39
WACC vs ROIC
6.11%
-1.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -3.40
ACT's Operating Margin % is ranked lower than
82% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. ACT: -3.40 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -14.8  Med: 2.28 Max: 14.12
Current: -3.4
-14.8
14.12
Net Margin % -25.88
ACT's Net Margin % is ranked lower than
79% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ACT: -25.88 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -28.83  Med: 5.43 Max: 102.76
Current: -25.88
-28.83
102.76
ROE % -5.93
ACT's ROE % is ranked lower than
72% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. ACT: -5.93 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 6.44 Max: 19.24
Current: -5.93
-11.23
19.24
ROA % -3.34
ACT's ROA % is ranked lower than
70% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. ACT: -3.34 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.33  Med: 3.67 Max: 11.31
Current: -3.34
-4.33
11.31
ROC (Joel Greenblatt) % -539.64
ACT's ROC (Joel Greenblatt) % is ranked lower than
88% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. ACT: -539.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -547.05  Med: 2.26 Max: 39.38
Current: -539.64
-547.05
39.38
3-Year Revenue Growth Rate -7.00
ACT's 3-Year Revenue Growth Rate is ranked higher than
92% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ACT: -7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14  Med: 17.35 Max: 54
Current: -7
-14
54
3-Year EPS without NRI Growth Rate -2.00
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. ACT: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.75 Max: 94.3
Current: -2
0
94.3
GuruFocus has detected 2 Warning Signs with Allergan PLC ACT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACT's 30-Y Financials

Financials (Next Earnings Date: 2018-05-11)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Allergan PLC does not have enough historical financial data to display Peter Lynch Chart.

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNpA.PFD543.502.535 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:XTER:MRK, TSE:4502, NYSE:ZTS, SHSE:600276, NAS:MYL, NSE:SUNPHARMA, TSE:4523, NYSE:TEVA, SHSE:600518, SHSE:600196, SZSE:000538, TSE:4507, XPAR:IPN, TSE:4508, NYSE:PRGO, OCSE:LUN, SZSE:000963, JSE:APN, XSWX:VIFN, HKSE:03320 » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products.

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Top Ranked Articles about Allergan PLC

Why Did Allergan Abandon the Shire Hunt? After moving to beat Takeda’s offer, the pharmaceutical company bailed almost immediately
When Takeda (TSE:4502) put Shire (NASDAQ:SHPG) into play a couple weeks ago, it looked to be the beginning of a serious hunt for the major biotech company. Takeda offered $62.5 billion for Shire, which had a pre-offer market cap of about $40 billion. Read more...
Shire’s Tug of War A closer look at the recent developments at Shire Plc, including the sale of its oncology business, label expansion of Vonvendi and the buyout bids from Allergan and Takeda Pharmaceuticals
Shire (SHPG) has caught a lot of attention this past week. First, on April 16, Shire announced the sale of its oncology business to Servier for $2.4 billion. The reason for this sale was to allow Shire to focus on its core business, which is rare diseases, and bolster Servier’s ambitions to become a global competitor within oncology. Read more...
Biotech M&A Ratchets Up to a New Level A flood of cash is causing an industry-wide feeding frenzy
Many biotech industry-watchers expected 2018 to be a big year for mergers and acquisitions, and the big players have not disappointed. Fueled by a massive infusion of cash repatriated from overseas thanks to the Trump tax law’s one-time tax holiday, the M&A boom has only just gotten started. Read more...
Allergan Showcases Leadership in Neurosciences with 25 Presentations at the American Academy of Neurology Annual Meeting in Los Angeles
Allergan Does Not Intend to Make an Offer for Shire plc; Strategic Review Continues
Allergan Issues Statement Regarding Press Speculation on its Strategic Review
New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM — Consolidated Revenues, Company Growth, and Expectations for 2018
Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression
Allergan Receives 2018 ENERGY STAR® Partner of the Year - Sustained Excellence Award

Ratios

vs
industry
vs
history
Forward PE Ratio 10.18
ACT's Forward PE Ratio is ranked higher than
88% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. ACT: 10.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.75
ACT's PB Ratio is ranked higher than
94% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACT: 0.75 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.72 Max: 5.9
Current: 0.75
0.69
5.9
PS Ratio 3.31
ACT's PS Ratio is ranked lower than
51% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. ACT: 3.31 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.09 Max: 10.64
Current: 3.31
0.99
10.64
Price-to-Free-Cash-Flow 10.74
ACT's Price-to-Free-Cash-Flow is ranked higher than
83% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. ACT: 10.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.27  Med: 19.22 Max: 287.96
Current: 10.74
7.27
287.96
Price-to-Operating-Cash-Flow 8.99
ACT's Price-to-Operating-Cash-Flow is ranked higher than
84% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. ACT: 8.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.06  Med: 15.16 Max: 93.15
Current: 8.99
6.06
93.15
EV-to-EBIT -8.67
ACT's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. ACT: -8.67 )
Ranked among companies with meaningful EV-to-EBIT only.
ACT' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 10.7 Max: 102.2
Current: -8.67
-310.4
102.2
EV-to-EBITDA -41.88
ACT's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. ACT: -41.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.1  Med: 12.55 Max: 106.9
Current: -41.88
-47.1
106.9
EV-to-Revenue 5.05
ACT's EV-to-Revenue is ranked lower than
64% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACT: 5.05 )
Ranked among companies with meaningful EV-to-Revenue only.
ACT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.6 Max: 18.1
Current: 5.05
1.2
18.1
Shiller PE Ratio 49.53
ACT's Shiller PE Ratio is ranked lower than
66% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.11 vs. ACT: 49.53 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96  Med: 57.23 Max: 2307.73
Current: 49.53
18.96
2307.73
Current Ratio 1.16
ACT's Current Ratio is ranked lower than
85% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACT: 1.16 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.47 Max: 13.07
Current: 1.16
1.03
13.07
Quick Ratio 1.06
ACT's Quick Ratio is ranked lower than
75% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. ACT: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2 Max: 11.98
Current: 1.06
0.8
11.98
Days Inventory 146.91
ACT's Days Inventory is ranked lower than
65% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. ACT: 146.91 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 108.18  Med: 125.89 Max: 369.45
Current: 146.91
108.18
369.45
Days Sales Outstanding 66.38
ACT's Days Sales Outstanding is ranked higher than
59% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. ACT: 66.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.91  Med: 66.34 Max: 197.04
Current: 66.38
43.91
197.04
Days Payable 54.63
ACT's Days Payable is ranked lower than
65% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ACT: 54.63 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.03  Med: 57.39 Max: 109.48
Current: 54.63
28.03
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ACT: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -7.5
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.65
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. ACT: 0.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.22 Max: 5.08
Current: 0.65
0.55
5.08
Price-to-Median-PS-Value 1.58
ACT's Price-to-Median-PS-Value is ranked lower than
78% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ACT: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.79 Max: 5.21
Current: 1.58
0.59
5.21
Earnings Yield (Greenblatt) % -11.52
ACT's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACT: -11.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.2  Med: 3 Max: 12.3
Current: -11.52
-12.2
12.3
Forward Rate of Return (Yacktman) % 13.58
ACT's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. ACT: 13.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.1  Med: 13.3 Max: 22.6
Current: 13.58
4.1
22.6

More Statistics

Revenue (TTM) (Mil) $15,940.70
52-Week Range $24.23 - 317.72
Shares Outstanding (Mil)392.44

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}